ELECT 24 Top Ad

2 Skin Disease Stocks React to Failed Eczema Drug

AnaptysBio's eczema drug failed a key trial

Managing Editor
Nov 8, 2019 at 2:39 PM
facebook X logo linkedin


The U.S. stock market is drifting lower to end the week, as Wall Street waits in limbo for any U.S.-China trade developments. Two stocks stocks making vastly different moves today are skin disease specialists AnaptysBio Inc (NASDAQ:ANAB) and Dermira Inc (NASDAQ:DERM). Here's a quick look at what's moving the shares of ANAB and DERM.

ANAB In Nasdaq Cellar After "Surprising" Eczema Drug Failure

AnaptysBio stock is down 70.6% at $10.62 at last check, after etokimab, the company's eczema drug, failed the main goal for its late-stage trial. Three brokerages promptly issued downgrades, Jefferies, who also slashed its price target to $12 from $120. RBC was "surprised" by the failure, and called out AnaptysBio for a lack of investor call for such an important event. ANAB earlier hit a record low of $10, and is on track for its worst day ever by a wide margin.

Options volume is usually light, but it's roared to life today. More than 2,700 calls have changed hands today, 20 times the average intraday amount and 31 times the number of puts traded. Leading the charge is the December 17.50 call, where new positions are being opened and sell-to-open activity detected. 

DERM The Benefactor From Etokimab Failure

On the other end of the spectrum, Dermira stock is up 21.5% to trade at $8.46, as AnaptysBio's eczema drug failures opens the door for Dermira's own treatment, lebrikizumab. Leerink says the etokimab failure removes "a major investor overhang." Derm is new eyeing its highest close in over a month. 

There's similar frenetic activity in DERM's normally quiet options pits. Nearly 2,000 calls have changed hands, six times the average intraday amount and volume pacing for the 97th percentile of its annual range. Leading the charge is the November 8 call, but there are also new positions being opened at the November 10 call. 

Now seems to be an affordable time for near-term traders to jump on Dermira stock with options. The stock's Schaeffer's Volatility Index (SVI) of 74% ranks in the low 8th percentile of its annual range, indicating low volatility expectations are being priced into short-term contracts.

 

Biden’s government just announced a new government "stimulus program"...

And it could hand you a payment for as much as $7,882 — each quarter.

See, it has to do with a recent 19-page memo from Biden’s office...

Directing the government to once again send a form of "stimulus payments" to the mailboxes of Americans during these difficult times.

Better still, you can collect these payouts every single quarter — for life...

Payments run as high as $7,882... And it only takes five minutes to sign up.

I call this the "Stimulus Stipends" program…

And Forbes recently declared that you can "retire rich" thanks to this program.

So if you want to start cashing in your quarterly payouts — courtesy of the U.S government...

Discover how to receive your FIRST "Stimulus Stipends" payment for up to $7,882 here. 
 (ad)
 

election 2024 report

                                                  AD                                                  
best AI trade you can make today…?
(it’s not MSFT, GOOGL, AMZN or AAPL)

                                                  AD                                                  

 
 

VOLATILITY SCORECARD

 


                                               AD                                                    
Crazy Opportunity!! Tiny AI Stock just $3
“This Type of AI Will Be Worth “Ten MSFTs.”

                                               AD                                                    

 
4 AI STOCKS TO BUY NOW
 

                                                  AD                                                  
best AI trade you can make today…?
(it’s not MSFT, GOOGL, AMZN or AAPL)

                                                  AD